Track AVTX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Avalo Therapeutics Inc
1500 Liberty Ridge Drive, Wayne, PA, United States, 19087
IPO
2015
Employees
33
Industry
Biotechnology
Sector
Healthcare
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20264-4
0
Q1 20261-1
0
2-quarter cumulative
5 sells0 buys
Analyst Ratings
2 analysts covering
Buy50%recommend buy
Buy
1
Hold
1
Sell
0